Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks

Area of Science:

• Biochemistry
• Genetics
• Cell Biology

Background:

• Mucopolysaccharidosis IVA (MPS IVA) is a rare genetic disorder caused by mutations in the N-acetylgalactosamine-6-sulfate-sulfatase (GALNS) gene.
• GALNS deficiency impairs the lysosomal degradation of glycosaminoglycans, leading to skeletal and non-skeletal complications.

Purpose of the Study:

• To review current in vitro and in vivo models used for studying MPS IVA pathogenesis.
• To identify the limitations of existing models for evaluating therapeutic strategies.

Main Methods:

• Review of existing literature on in vitro (fibroblast, chondrocyte) and in vivo (mouse) models for MPS IVA.
• Analysis of the suitability of these models for recapitulating human disease phenotypes.

Main Results:

• Current in vitro models, primarily fibroblasts, offer insights but may not fully represent chondrocyte involvement in MPS IVA.
• Existing mouse models lacking GALNS expression often fail to accurately replicate the skeletal dysplasia observed in human patients.

Conclusions:

• There is a need for improved MPS IVA models that better reflect the disease's skeletal manifestations.
• Limitations in current models may impact the accurate assessment of drug efficacy and disease mechanisms.